Dr. McCollum on Treatment in the First-Line Setting for CRC

A. David McCollum, MD
Published Online: Thursday, Nov 16, 2017



A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

According to McCollum, there was a burst of activity in the early part of this millennia with the approval of many agents. It was discovered that there were some molecular predictors to optimize regimens for particular forms of CRC.

RAS, BRAF, and HER2 testing might specify certain regimens for patients. Additionally, the sidedness of the tumor may predict which treatment will be successful, explains McCollum.
 


A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

According to McCollum, there was a burst of activity in the early part of this millennia with the approval of many agents. It was discovered that there were some molecular predictors to optimize regimens for particular forms of CRC.

RAS, BRAF, and HER2 testing might specify certain regimens for patients. Additionally, the sidedness of the tumor may predict which treatment will be successful, explains McCollum.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to BedsideDec 29, 20171.5
Cancer Summaries and Commentaries™: Update from San Diego—Advances in the Treatment of Myeloproliferative NeoplasmsDec 29, 20172.5
Publication Bottom Border
Border Publication
x